AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02111785 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Burr Hole Craniostomy
Description: Treatment with surgical burr hole craniostomy and evacuation of SDH
Study NCT02358798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 years-assessment of respiratory function
Study NCT00004011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00004011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00004011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study NCT00004011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT04515121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tCES
Description: The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
Study NCT04515121 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tCES
Description: The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
Study NCT04515121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb rehabilitation
Description: Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living. Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
Study NCT04515121 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lower limb rehabilitation
Description: Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living. Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
Study NCT01654991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Screening
Description: Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
Study NCT01654991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Screening
Description: Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
Study NCT02798211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab 300 mg
Description: 150 mg x 2 s.c. injection
Study NCT02798211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab 150 mg
Description: 150 mg s.c. injection
Study NCT02798211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01538108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA Balloon catheter with paclitaxel
Description: patients treated by the NMB's PTA Balloon catheter with paclitaxel
Study NCT01538108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plain Balloon angioplasty (PBA)
Description: PBA
Study NCT03060564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tendon graft
Description: JRF Orthopedics Tendon Graft
Study NCT03060564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No intervention
Study NCT04538989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ358 Sequential Group Cohort 1
Description: IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
Study NCT04538989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ358 Sequential Group Cohort 2
Description: IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
Study NCT04538989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ358 Sequential Group Cohort 3
Description: IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
Study NCT04538989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ358 Sequential Group Cohort 4
Description: IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
Study NCT02337517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02337517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT02070900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POC CD4
Description: Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
Study NCT02070900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programmatic Mentoring
Description: Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
Study NCT03600896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107
Description: Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~* 5 mcg/kg/dose for 3 doses~* 10 mcg/kg/dose for 3 doses~* 20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II.
Study NCT03237520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy
Description: VRT software and device is developed in collaboration with IIT Delhi using Kinect system. Kinect- motion sensor and computer set up is required. VRT (CIMT in a virtual environment)will be provided for 2 hours at every visit(twice weekly for first 4 weeks, once a week for next 4 weeks). VRT will be provided only during scheduled visits with the same principle as mCIMT. Functional activities like repetition of the tasks and shaping will be performed with the affected hand using VRT and CIMT while the unaffected arm is restrained
Study NCT03237520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mCIMT
Description: Modified constraint induced movement therapy will be provided to all children according to predefined protocol.
Study NCT03046511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
Study NCT03046511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
Study NCT01835600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP
Description: PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
Study NCT04183634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine TTS (Test)
Description: Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.
Study NCT04183634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine TTS (Test)
Description: Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.
Study NCT04183634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupro (Reference)
Description: Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.
Study NCT04183634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupro (Reference)
Description: Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.
Study NCT01350141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An infusion lasting approximately 60 minutes
Study NCT01350141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: An infusion lasting approximately 60 minutes
Study NCT02607657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg
Study NCT02607657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Study NCT02607657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg
Study NCT02607657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg twice a day
Study NCT02607657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg twice a day
Study NCT01185743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine 10mg od + placebo od
Study NCT01185743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: ziprasidone 40mg td
Study NCT01231841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given orally
Study NCT01231841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT05357937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard physiotherapy program
Description: A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups
Study NCT04250337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection
Study NCT04250337 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT04250337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid
Description: Topical Corticosteroid
Study NCT04250337 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Corticosteroid
Description: Topical Corticosteroid
Study NCT05398146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mathematical operations
Description: Prepared by the researchers, the form involved mathematical operations such as addition, subtraction, multiplication, and division. The difficulty level of the mathematical operations in the form was determined by age groups of children. Accordingly, mathematical operations were divided into 3 groups primary school, secondary school and high school levels.
Study NCT05398146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ball squeezing
Description: For the children in the BS group, a softball that could fit in the palm and be easily squeezed by the child was used.
Study NCT04456049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 40 mg oral tablets once daily for a maximum of 28 days.
Study NCT04456049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 40 mg oral tablets once daily for a maximum of 28 days.
Study NCT01855997 — intervention group
Intervention type: DRUG
Intervention: Peg-IFN alfa-2a
Description: Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
Study NCT04364022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: 2x 200mg/50mg, twice daily for 5 days (bid, PO)
Study NCT05800483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healium
Description: web-based platform to elicit patients' preferences about prostate cancer treatment and designed for low health literature populations
Study NCT01364545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ketone ester drink
Description: Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
Study NCT01364545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo (carbohydrate containing) drink
Description: Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
Study NCT03866434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD422
Description: Participants will receive 1 mg of SPD422 (2\*0.5 mg) capsule orally on Day 1 and 8 in fasted state.
Study NCT03866434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.
Study NCT01304251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short-term fasting
Description: Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy
Study NCT01304251 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Healthy nutrition
Description: Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
Study NCT00094497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT00094497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT00094497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT00094497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptozotocin
Study NCT00094497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitotane
Study NCT01475370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-501
Description: 1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose.
Study NCT03735641 — intervention group
Intervention type: PROCEDURE
Intervention: Expanded Pedicled Deltopectoral Flap
Description: Expanded Pedicled Deltopectoral Flap is a type of surgical flap
Study NCT02538471 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
Study NCT02538471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Drug
Description: Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
Study NCT01185743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo td
Study NCT05398146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: listening to music
Description: Children were allowed to listen to music with headphones during dressing changes.
Study NCT05398146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kontrol grubu
Description: No application was made during dressing change in children. Routine dressing change of the clinic was applied.
Study NCT00613288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo
Description: The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~1. Placebo (hypogonadism after leuprorelide injection)~2. Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~3. Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~4. No treatment.
Study NCT00706225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene and conjugated estrogens
Description: Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
Study NCT05496621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: 1st Stage Keele Start MSk tool translated into Turkish and its cultural adaptation, 2nd Stage Statistical analysis of reliability and validity of Turkish Keele start msk tool
Study NCT04175301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Each hydrogen tablet contains 80 mg magnesium
Study NCT04175301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matching placebo tablet also contains 80 mg magnesium
Study NCT01337414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VMS diary booklet
Study NCT01337414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study NCT02100150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Study NCT02100150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored solution 0.5% v/v in Water for Injection
Study NCT03620838 — intervention group
Intervention type: DRUG
Intervention: oral contraceptive pill, oral progesterone
Description: ovarian endometrioma cyst excision
Study NCT02508532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets
Study NCT00883038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diabetic diet following the DNSG guidelines
Description: The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
Study NCT00883038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-fat vegetarian diet
Description: The low-fat vegetarian diet (\~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
Study NCT04845724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diet
Study NCT04845724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Diet
Study NCT01694602 — intervention group
Intervention type: BIOLOGICAL
Intervention: (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)
Description: Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
Study NCT02826122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pai APP
Description: Prescription: Target 100 PAI Points per week
Study NCT02826122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit APP
Description: Prescription: Target daily 10.000 steps
Study NCT04307706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in six sessions. The duration of each session lasted on average 60-90 minutes. A session was held for each parent once a week.
Study NCT00927355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
Study NCT00927355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician.
Study NCT03485014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: EXPAREL 4 mg/kg
Study NCT00641719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: Duloxetine 40 mg QD, PO, 1 year
Study NCT00641719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: Duloxetine 60 mg QD, PO, 1 year
Study NCT02981381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEST-1
Description: The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.